ABSTRACT: Eosinophilic asthma (EA) is a severe subphenotype of asthma. Patients with EA historically suffer from frequent and severe asthma exacerbation, declining lung function, and oral-steroid dependency, as well as decreased quality of life and the risk for poor health outcomes. Biologic therapies target the eosinophil inflammatory response, and they have been found to reduce asthma exacerbations and hospitalizations, decrease oral-corticosteroid use, improve lung function, and result in better overall quality of life for these refractory patients.
展开▼
